Endothelial Injury and Repair as a Working Paradigm

Similar documents
How does Exercise Work at the Cellular/Molecular Level

PCTH 400. Endothelial dysfunction and cardiovascular diseases. Blood vessel LAST LECTURE. Endothelium. High blood pressure

ENDOTHELIAL PROGENITOR CELLS AS A NOVEL BIOMARKER OF VASCULAR HEALTH

Microvascular Disease: How to Diagnose and What s its Treatment

115 Endothelial Progenitor Cells: A Novel Laboratory-Based Biomarker of Vascular Health. Ishwarlal Jialal

Adenosine stimulates the recruitment of endothelial progenitor cells to the ischemic heart

DECLARATION OF CONFLICT OF INTEREST

The Study of Endothelial Function in CKD and ESRD

DECLARATION OF CONFLICT OF INTEREST. No conflicts of interest

Coronary microvascular dysfunction after elective percutaneous coronary intervention: correlation with exercise stress test results

Endothelial PGC 1 - α 1 mediates vascular dysfunction in diabetes

Myocardial infarction

Intolerance in Heart Failure

Statins and endothelium function

Role of Inflammation in Pulmonary Hypertension

Enhancing Treatment for Cardiovascular Disease: Exercise and Circulating Angiogenic Cells

Reprogramming through micrornas Stefanie Dimmeler

Assessment of Ischemia and Viability

Ischemia and Reperfusion: Pharmacological treatment options

Effets Vasculaires des Flavonoïdes Alimentaires et leurs Mécanismes

Cancer therapy, cardiovascular toxicity and hypertension

Control of Myocardial Blood Flow

Cardiovascular Protection and the RAS

Management of In-stent Restenosis after Lower Extremity Endovascular Procedures

PhD THESIS Epigenetic mechanisms involved in stem cell differentiation

Conflict of Interest Slide

World Journal of Cardiology. Circulating endothelial and progenitor cells: Evidence from acute and long-term exercise effects

Myocardial Perfusion: Positron Emission Tomography

Professor Harvey White. Interventional Cardiologist Auckland

Pathophysiology of Coronary Microvascular Dysfunction

ESC CONGRESS 2010 Stockholm, august 28 september 1, 2010

In stable ischemic vascular syndromes, exercise has been. Exercise Physiology

WHY ADMINISTER CARDIOTONIC AGENTS?

63 yo woman with chest pain

Recovery of Myocardial Infarction via Unique Modulation of the Cardiac Microenvironment

Fractional Flow Reserve: Basics, FAME 1, FAME 2. William F. Fearon, MD Associate Professor Stanford University Medical Center

State of the Art. Advances in Cardiovascular Imaging. ESC Congres Stockholm September 1, 2010 Frank E. Rademakers, MD, PhD, FESC

CURRENT STATUS OF STRESS TESTING JOHN HAMATY D.O.

The Role of Massage in Blood Circulation, Pain Relief, and the Recovery Process: Implications of Existing Research

Paracrine Mechanisms in Adult Stem Cell Signaling and Therapy

Revascularization in Severe LV Dysfunction: The Role of Inducible Ischemia and Viability Testing

Cardiovascular Imaging Stress Echo

Exercise Intolerance in Heart Failure: Significance of Skeletal Muscle Abnormalities

Current Role of Renal Artery Stenting in Patients with Renal Artery Stenosis

Dyslipidemia Endothelial dysfunction Free radicals Immunologic

Inflammatory Markers and Anti- Inflammatory Effects of Insulin

Nox-Dependent Mechanisms of Cardiomyocyte Dysfunction in a Model of Pressure Overload

How to Evaluate Microvascular Function and Angina. Myeong-Ho Yoon Ajou University Hospital

In the name of GOD. Animal models of cardiovascular diseases: myocardial infarction & hypertension

Maria Angela S. Cruz-Anacleto, MD

Cardiovascular disease, studies at the cellular and molecular level. Linda Lowe Krentz Bioscience in the 21 st Century September 23, 2009

Women and Coronary Artery Disease:

Cell Therapy Update what have we learned from clinical trials?

Update on stem cells in cardiovascular disease

ESC Congress August 2011 Paris France. VEGFs and the angiogenic paradox in diabetic patients

Hypothesis: When compared to conventional balloon angioplasty, cryoplasty post-dilation decreases the risk of SFA nses in-stent restenosis

Relationship between serum glutathione peroxidase-1activity with endothelial dysfunction level in patients with coronary artery diseases

Personalized Medicine: An

Cardiac evaluation for the noncardiac. Nathaen Weitzel MD University of Colorado Denver Dept of Anesthesiology

Vascular disease. Structural evaluation of vascular disease. Goo-Yeong Cho, MD, PhD Seoul National University Bundang Hospital

Metabolic Syndrome Is A Key Determinant Of Coronary Microvascular Function In Patients With Stable Coronary Disease Undergoing PCI

Diminished Circulating Monocytes after Peripheral Bypass Surgery for Critical Limb Ischemia

BIOAUTOMATION, 2009, 13 (4), 89-96

Effects of Cardiovascular Risk Factors on Endothelial Progenitor Cell

The dynamic regulation of blood vessel caliber

Financial Disclosures. Bone Marrow Mononuclear Cells. Cell Based Therapies: What Do They Do and Will They Work in CLI?

Endothelial Dysfunction in Obesity. Justin D. La Favor. November, 2012

Steven S. Saliterman, MD, FACP

How to detect early atherosclerosis ; focusing on techniques

Mandatory knowledge about natural history of coronary grafts. P.Sergeant P. Maureira K.U.Leuven, Belgium

New Insight about FFR and IVUS MLA

Coronary Artery Disease in the 21 st Century: An Integrated Approach Based on Science and Art

SHOCKWAVE THERAPY FOR REFRACTORY ANGINA PECTORIS

Clinical Significance of Aldosterone Levels and Low Grade Inflammation in Patients with Coronary Vasospasm

Update on Tack Optimized Balloon Angioplasty (TOBA) Below the Knee. Marianne Brodmann, MD Medical University Graz Graz, Austria

NAM JUNE PAIK: Rhapsody in Video

THE CARDIOVASCULAR INFLAMMATORY CONTINUUM DR AB MAHARAJ

CHRONIC HEART FAILURE : WHAT ELSE COULD WE OFFER TO OUR PATIENTS? Cardiac Rehabilitation Society of Thailand

Diabetes and the Heart

Viability Testing Using Dynamic Echocardiography

LM stenting - Cypher

Stem Cells. Keith Channon. Department of Cardiovascular Medicine University of Oxford John Radcliffe Hospital, Oxford

Classification of Endothelial Dysfunction. Stefano Taddei Department of Internal Medicine University of Pisa, Italy

Estrogens vs Testosterone for cardiovascular health and longevity

Erythropoietin preserves the endothelial differentiation potential of cardiac progenitor cells and attenuates heart failure during anti-cancer therapy

ENDOGENOUS CARDIAC STEM CELLS IN THE REGENERATION OF ACUTE AND CHRONIC ISCHEMIC MYOCARDIUM

Hybrid cardiac imaging Advantages, limitations, clinical scenarios and perspectives for the future

and Restenosis Yangsoo Jang, MD, PhD. Yonsei University College of Medicine

For more information about how to cite these materials visit

What the Cardiologist needs to know from Medical Images

Mesenchymal Stem Cells to Repair Vascular Damage after Chemotherapy: Past, Present and Future

Implications of the New ESC/EACTS Guidelines for Myocardial Revascularization in 2011

TSP1 Secr Sec eted eted b m byy m n a y n y ce c ll cee s Upregulated by injury/stress W dely expressed CD47 S TSP1 only known ligand

Perioperative Myocardial Infarction

Reactive oxygen species: Importance for ischemia/reperfusion (injury)

Impact factor: Reporter:4A1H0019 Chen Zi Hao 4A1H0023 Huang Wan ting 4A1H0039 Sue Yi Zhu 4A1H0070 Lin Guan cheng 4A1H0077 Chen Bo xuan

AQUATIC ACTIVITY & THE BRAIN AQUATIC EXERCISE AND BLOOD VESSEL COMPLIANCE

PCI for Left Main Coronary Artery Stenosis. Jean Fajadet Clinique Pasteur, Toulouse, France

Fractional Flow Reserve (FFR) --Practical Set Up Pressure Measurement --

Effects of the angiotensin II type-1 receptor antagonist telmisartan on endothelial activation induced by advanced glycation endproducts

Transcription:

Endothelial Injury and Repair as a Working Paradigm A. Linke ESC Meeting 2010 UNIVERSITÄTLEIPZIG H ERZZEN TRUM

Physiology of Endothelial Function: Regulation of Vascular Tone L-Arg. L-Arg. Agonists Shear Stress Vascular Lumen Gefäßlumen L-Arg. L-Arg. + enos + Citrullin L-Citrulline Endothelial Endothelzelle Cell L-Arg. NO Extrazellularraum Extracellular Space NO GTP cgmp Ca 2+ Glatte Gefäßmuskelzelle Vascular Smooths Muscle Peroxynitrite

Pathophysiology Endothelial Dysfunction The conditio sine qua non for atherogenesis J. Ross, Nature 1993;362:801-809

Pathophysiology of Endothelial Dysfunction in Cardiovascular Disease L-Arg. L-Arg. Vascular Lumen Gefäßlumen L-Arg. L-Arg. enos enos Citrullin L-Citrulline Endothelial Endothelzelle Cell L-Arg. NO ROS Extrazellularraum Extracellular Space NO GTP cgmp Ca 2+ Glatte Gefäßmuskelzelle Vascular Smooths Muscle Peroxynitrite

Therapeutic options in CAD: Exercise Training

Assessment of Endothelial Function Infusion Catheter Doppler Guide Wire, 12 MHz Coronary Artery ( target vessel ) 1 cm Distal Diameter

Shear Stress, Physical Activity and Endothelial Function Inclusion Criteria Coronary 1/2 Vessel Disease Preserved LV Function Stenosis Requiring Intervention Endothelial Dysfunction in Another Coronary Artery = Target Vessel Study Design Stable CAD (19 Pat.) Assessment of Endothelial Function Ergometer-Training 6x/d for 4 Weeks Control 4 Wo. Acetylcholine Assessment of Endothelial Function Hambrecht R, N Engl J Med 2000(342):454-60

Shear Stress, Physical Activity and Endothelial Function Training Group Control Group 300 300 D Coronary Blood FLow [%] 200 100 0 200 100 0-100 -100 Begin 4 Weeks Begin 4 Weeks p<0.05 vs.kontrolle Hambrecht R, N Engl J Med 2000(342):454-60

Molecular Mechanisms: Exercise Training

Activation of enos by shear stress Shear stress Vessel PDK PI3K Akt P P S 1177 HSP90 Endothelium P enos P

LIMA-Study: Design Patients with stable CAD and indication for CABG (n=35) In-vivo-Assessment of Endothelial Function (LIMA) Control (n=18) Usual care 4 weeks Training (n=17) Daily Raw- / Bicycle ergometer training (4-6/d), 4 weeks In-vivo-Assessment of Endothelial Function (LIMA) In-vitro-Assessment of Endothelial Function (LIMA-Ring), Molecular Analysis of RNA- and Protein Expression Hambrecht R. et al., Circulation 2003

D APV vs. Baseline [%] Relaxation [%] Impact of exercise training on average peak blood flow velocity (APV) and Vasorelaxation of the LIMA ACH-induced APV after 4 weeks: - in vivo - Acetylcholine-induced Relaxation - in vitro - 120 80 40 0 p < 0.05 vs. Control Training Control 0.072 0.72 7.2 0-25 -50-75 -100 p<0.05-10 -8-6 -4 Control Training Acetylcholine [µmol/l] Acetylcholine [µmol/l] Hambrecht R. et al., Circulation 2003

enos-expression [rel. Units] Protein expression [rel. units] Impact of Exercise Training on enos-expression and -Phosphorylation enos-expression C T C T enos-phosphorylation (Ser1177) K K T T 1.5 p<0.05 1.5 p<0.01 1.0 0 1.0 0.5 0.5 0.0 Control Training 0.0 Control Training Circulation 2003 (107):3452

D APV [rel. Units] Association between enos Ser1177 and DAPV 20 r=0.59 p< 0.02 Exercise Training Group 10 0 1 2 3 p-enos Ser1177 [rel. Units] Hambrecht et al., Circulation 2003

NAD(P)H Oxidase - Subunits O 2 - O2 Rac Rap1A p47 gp91 p67 p22 Aktivation Phosphorylation NADPH NADP + Rap1A Rac gp91 p47 P p22 p67 Different Isoforms of gp91 phox described: Nox1 to Nox5, Nox2 = gp91 phox (Cheng et al., Gene 2001) In vessels: Nox-1, Nox-2 und Nox-4 mit relevanter Aktivität In endothelial cells: Nox-2 In vascular smooth muscle cells: Nox-1 und Nox-4

Gp91 phox / 18S-rRNA [x100] Nox4 / 18S-rRNA [x100] p22 phox / 18S-rRNA [x100] Expression of NAD(P)H Oxidase Subunits gp91 phox Nox4 p22 phox 100 7.5 3 75 5.0 2 50 25 2.5 1 0 Control Training 0.0 Control Training 0 Control Training Adams V et al., Circulation 2005

NAD(P)H Oxidase-Activity and ROS-Production: Impact of Exercise Training NAD(P)H-Oxidase-Aktivity ROS-Generation NAD(P)H-Oxidase-Activity [mu/mg] 7.5 5.0 2.5 0.0 Control p<0.05 Training ROS-Generation [DOD 550 / min] 0.100 0.075 0.050 0.025 0.000 Control p<0.05 Training Adams V et al., Circulation 2005

Correction of Endothelial Dysfunktion by Exercise Training Endotheliale Dysfunktion O 2 - NO Exercise Training O 2 - NO enos Expression p-ecnos and p-akt NAD(P)H subunits p22 phox and gp91 phox Ang II-Receptor 1 Prognostic Implication?

Molecular Mechanisms: Importance of endogenous progenitor and stem cells

Function of EPCs Bone marrow Proliferation EPC Blood vessel Endothelium Recruitment Differentiation Mobilization Target organ Vasculogenesis in-situ EPC differentiation and proliferation

Application of ex vivo cultivated EPCs - Results from animal models - human human Medium mature EC EPCs Immediately after ischemia MNCs 7 days in culture 28 days after EPC application Animal model of Hind limb ischemia Kalka C et al., PNAS 2000; 97:3422

Progenitor Cells Regenerate Damaged Endothelium - Results from animal experiments - Friedrich E et al., Circ Res 2006; 98:e20

Apoptotic index Apopt. Endothelial Cells [%] Endothelial Integrity: Turnover of Endothelial Cells Oxidant stress oxldl Rössig L, J Am Coll Cardiol 2000(36):2081 Di-LDL/FITC-Lectin positive Cells Angiotensine II Catecholamine Cytokines Endotoxin Growth factor deficiency Control CHF Bone marrow Proapoptotic factors Endothelial progenitor cells Apoptosis

Molecular Mechanisms: Impact of ischemia on EPC release

Impact of an acute bout of exercise on EPC release Myocardial Ischemia (I) Pts with CAD and exercise induced ischema Control (C) Pts with CAD having no evidence of exercise-induced ischemia Healthy Subjects (HS) maximal symptom-limited bicycle ergometry Blood samples at 2, 4, 6, 8, 24, 48, 72, 96, 120 and 144h after the exercise test FACS-Analysis: Detection of CD34+/KDR+ cells in the blood Cell culture: Measurement of Di-acLDL/FITC-lectin positive cells after 4 days in culture Adams et al., Arterioscler Thromb Vasc Biol 2004

x-fold increase in CD34 + /KDR + cells vs. begin Impact of an acute bout of exercise on EPC mobilization 4 $ # Healthy subjects (HS) CAD without Ischemia (C) 3 2 $ # CAD with ischemia (I) $: p<0.05 vs. Beginn; #: p<0.05 vs. C and HS 1 0 0 2 4 6 8 24 48 72 96 120 144 Time after exercise [h] Adams et al., Arterioscler Thromb Vasc Biol 2004

EPC-Mobilisation by Exercise Training: Results of 2 randomized studies Patients with PAOD Fontaine II b (n=18) Maximal Exercise Test on the Treadmill Blood sampling Patients CAD with patients PAOD after PTA (n=31) (n=18) Maximal max. exercise Exercise test Test on a on treadmill the Treadmill blood Blood samples sampling Ischemic Training (n=9) Inactive Control (n=9) Non-ischemic ET ET below at the AP-Threshold 75% of peak HR (n=15) (n=9) Inactive Inactive control Control (n=16) (n=9) Blood sampling (every week) blood Blood samples sampling (every (weekly) week) Maximal Exercise Test after 4 weeks Sandri M, et al; Circulation 2005

EPC Mobilization by Exercise Training Begin Circulating CD34 + /KDR + Cells Begin acldl + /Lectin + Zellen After 4 weeks After 4 weeks Sandri M, et al; Circulation 2005

x-facher x-fold increase Anstieg in CD34 CD34 + /KDR + /KDR + Zellen + cells vs. Beginn x-fold increase in CD34 + /KDR + cells vs. Begin EPC Mobilization by Exercise Training Ischemic Training Non-ischemic Training 6 5 4 p<0.05 vs. Kontrolle Control Training Training 6 5 4 PAOD-Patients CAD after patients PTA 3 3 2 1 0 Kontrolle Control 2 1 0 Training Control Control Training 0 7 14 21 28 Time Zeit [d] [d] 0 7 14 21 28 Time time [d] Sandri M, et al; Circulation 2005

Impact of Exercise Training on the Expression of Homing Factors Non-ischemia Training (n=9) Ischemic Training (n=9) mrna-expression [arb. units] mrna-expression [arb. units] CXCR4 and CPC-Homing in ischemic tissues Migration following An SDF1- Gradient CPC CXCR4 SDF-1 Ischemia CXCR4-Expression in patients with PAOD 8 7 6 5 4 3 2 1 0 18 16 14 12 10 8 6 4 2 0 Begin 4 Wo Begin 4 Wo Training Control Begin 4 Wo Begin 4 Wo Training Control Sandri M, et al; Circulation 2005 p<0.05 vs. Begin and Control

Nicht-ischäm. Training % integrated CPCs Ischäm. Training % integrated CPCs Impact of Exercise Training on EPC function Matrigel-Assay 35 30 25 Patients with PAOD 20 15 10 5 Begin 4 Wo Begin 4 Wo Training (n=9) Control (n=9) 35 30 blue = nucleus red = endothelial cells green = EPCs 25 20 15 10 5 Beginn 4 Wo Begin 4 Wo Training (n=9) Control (n=9) Sandri M, et al; Circulation 2005 p<0.05 vs. Control

Impact of Exercise Training on the Mobilization of EPCs Improvement of myocardial Perfusion Endothelial Regeneration?? Arterio-/ Vasculogenesis Ischemia (HIF1a ) PI3K pakt NO circulating EPCs VEGF

Thank you!